Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Sonnenblick, Amir ^a   Brohée, Sylvain ^a   Fumagalli, Debora ^a   Vincent, Delphine ^a   Venet, David ^a   Ignatiadis, Michail ^a   Salgado, Roberto ^a   Eynden, Gert ^a   Rothé, Françoise ^a   Desmedt, Christine ^a   Neven, Patrick ^b   Loibl, Sibylle ^c   Denkert, Carsten ^d   Joensuu, Heikki ^e   Loi, Sherene ^f   Sirtaine, Nicolas ^a   Kellokumpu Lehtinen, Pirkko Liisa ^g   Piccart, Martine ^a   Sotiriou, Christos ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c SANA KLINIKUM OFFENBACH   (Germany)

^d Charité Campus Benjamin Franklin Medical Center   (Germany)

^e UNIVERSITY OF HELSINKI   (Finland)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Breast cancer; FinHer; HER2; Phosphorylated STAT3; Randomised trial; Trastuzumab resistance

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENHANCER-BINDING PROTEIN AP-3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR; TRASTUZUMAB;

ADULT; AGED; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; MIDDLE AGED; PHOSPHORYLATION; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRASTUZUMAB;

EID: 84938218723     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0416-2     Document Type: Article

References (33)

1. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-20.
2. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-83.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72.
4. Hudis CA. Trastuzumab - Mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51.
5. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007;26:3637-43.
6. Levy DE, Lee C. What does Stat3 do? J Clin Invest. 2002;109:1143-8.
7. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene. 2000;19:5419-27.
8. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A. 2001;98:7319-24.
9. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000-8.
10. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia New York N. 2013;15:848-62.
11. Azare J, Doane A, Leslie K, Chang Q, Berishaj M, Nnoli J, et al. Stat3 mediates expression of autotaxin in breast cancer. PLoS One. 2011;6, e27851.
12. Sonnenblick A, Shriki A, Galun E, Axelrod JH, Daum H, Rottenberg Y, et al. Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin Transl Oncol. 2012;14:232-6.
13. Sonnenblick A, Uziely B, Nechushtan H, Kadouri L, Galun E, Axelrod JH, et al. Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2013;138:407-13.
14. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798-809.
15. Responsify. www.responsify-fp7.eu
16. Gene Expression Omnibus. Gene profiling of HER2 breast cancer patients treated with adjuvant trastuzumab. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=ulwbuuwgpzqphsh&acc=GSE58984 .
17. Gene Expression Omnibus. FinHER trial: Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=wfermmkijzktzcb&acc=GSE65095 .
18. cBioPortal for Cancer Genomics. www.cbioportal.org/public-portal/index.do .
19. Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545-50.
21. Korkaya H, Kim G, Davis A, Malik F, Henry NL, Ithimakin S, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47:570-84.
22. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She Q-B, Maurer M, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007;104:7564-9.
23. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol. 2012;30:1996-2004.
24. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009;15:68-74.
25. Desmedt C, Majjaj S, Kheddoumi N, Singhal SK, Haibe-Kains B, El Ouriaghli F, et al. Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. Clin Cancer Res. 2012;18:1004-14.
26. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
27. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518-27.
28. Osmanbeyoglu HU, Pelossof R, Bromberg JF, Leslie CS. Linking signaling pathways to transcriptional programs in breast cancer. Genome Res. 2014;24:1869-80.
29. Tell RW, Horvath CM. Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors. Proc Natl Acad Sci U S A. 2014;111:12787-92.
30. Li G, Zhao L, Li W, Fan K, Qian W, Hou S, et al. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget. 2014;5:8317-29.
31. Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014;44:403-11.
32. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res. 2003;9:594-600.
33. Sansone P, Bromberg J. Targeting the Interleukin-6/Jak/Stat pathway in human malignancies. J Clin Oncol. 2012;30:1005-14.